Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Moderna posted a quarterly loss of $3.63 billion, half of which was accounted for by unused Covid-19 shots past their expiration date.
Shares of Starbucks jumped more than 9% Thursday after the company posted better-than-expected Q4 earnings.
Logistical holdups at ports in Brazil combined with poor sugar crops in other major sugar-producing nations is stretching supply of the crop.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
On Tuesday, the Biden administration approved the construction of a massive wind farm off the coast of Virginia.
While the price of aluminum has climbed off the mat in recent months, it’s still well below the heady days of early 2022.
Salmon fishers in Alaska face a cascade of challenges as state regulators implement a series of restrictions to prevent overfishing.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
WPP issued a reduction of its profit outlook for the second time in consecutive quarters on Thursday, citing major headwinds.
The good news is that GM generated about $3.1 billion in profit in the quarter. The bad news is that this is the only good news.
The European Space Agency has contracted Elon Musk’s SpaceX to launch navigation satellites next year, The Wall Street Journal reported.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.